Main article

Genomic Health (Redwood City, Calif.) has launched its Oncotype DX colon cancer test, a 12-gene test developed for the assessment of risk of recurrence in patients with stage II colon cancer. The laboratory-developed gene expression test is available exclusively through Genomic Health’s CLIA-certified laboratory.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

March 2010 - Table of Contents

DTTR March 2010 (Full PDF Issue)

IVD Companies, Labs Expand Personalized Medicine Plays

SACGHS Finalizes Recommendations on Gene Patents

Navigenics Raises $18 Million from Investors Including P&G

CancerGuide Diagnostics Partners with LabCorp, Looks to Raise $10.5 Million

Agilent Divests Clinical Diagnostics Business Hycor Biomedical

With Focus on Clinical Toxicology and Forensic Testing, NMS Labs Succeeds as a ‘Lab’s Lab’

Special Focus: Personalized Medicine: Biomarker Could Help Treatment Selection for Rheumatoid Arthritis

Special Focus: Personalized Medicine: Geisinger and TGen Partner for Personalized Medicine Initiative

Special Focus: Personalized Medicine: Researchers Map Genetic Variations Across 26 Cancers

Special Focus: Personalized Medicine: Clarient Launches IHC Test to Aid in Selection of Lung Cancer Therapy

Special Focus: Personalized Medicine: Pfizer and Qiagen to Develop Companion Diagnostic for Brain Tumor Patients

Special Focus: Personalized Medicine: JAMA Study Finds Genetic Links to Lung Cancer Survival

Special Focus: Personalized Medicine: Genomic Health Introduces Colon Cancer Test

Surgical Pathology Topped $1 Billion in Part B Charges in ’08

Myriad Genetics Inks Deal with Mammography Reporting System to Identify Potential Patients

Medco Health Services Acquires DNA Direct

IVD Stocks Slip 4%; Cepheid, Sequenom Join Index

DTTR G2 Insider (March 2010)

Vanderbilt Launches CardioDX Test for Coronary Artery Disease